170 related articles for article (PubMed ID: 22644029)
1. Resistance to a novel antichlamydial compound is mediated through mutations in Chlamydia trachomatis secY.
Sandoz KM; Eriksen SG; Jeffrey BM; Suchland RJ; Putman TE; Hruby DE; Jordan R; Rockey DD
Antimicrob Agents Chemother; 2012 Aug; 56(8):4296-302. PubMed ID: 22644029
[TBL] [Abstract][Full Text] [Related]
2. Variation in the mutation frequency determining quinolone resistance in Chlamydia trachomatis serovars L2 and D.
Rupp J; Solbach W; Gieffers J
J Antimicrob Chemother; 2008 Jan; 61(1):91-4. PubMed ID: 18033786
[TBL] [Abstract][Full Text] [Related]
3. An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics.
Benamri I; Azzouzi M; Sanak K; Moussa A; Radouani F
Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):59. PubMed ID: 34479551
[TBL] [Abstract][Full Text] [Related]
4. A series of ceramide analogs modified at the 1-position with potent activity against the intracellular growth of Chlamydia trachomatis.
Saied EM; Banhart S; Bürkle SE; Heuer D; Arenz C
Future Med Chem; 2015; 7(15):1971-80. PubMed ID: 26496536
[TBL] [Abstract][Full Text] [Related]
5. The chlamydial functional homolog of KsgA confers kasugamycin sensitivity to Chlamydia trachomatis and impacts bacterial fitness.
Binet R; Maurelli AT
BMC Microbiol; 2009 Dec; 9():279. PubMed ID: 20043826
[TBL] [Abstract][Full Text] [Related]
6. Cloning and characterization of a secY homolog from Chlamydia trachomatis.
Gu L; Remacha M; Wenman WM; Kaul R
Mol Gen Genet; 1994 May; 243(4):482-7. PubMed ID: 8202093
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the Protein Phosphatase CppA Alters Development of Chlamydia trachomatis.
Claywell JE; Matschke LM; Plunkett KN; Fisher DJ
J Bacteriol; 2018 Oct; 200(19):. PubMed ID: 30038048
[TBL] [Abstract][Full Text] [Related]
8. Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis.
Shima K; Szaszák M; Solbach W; Gieffers J; Rupp J
Antimicrob Agents Chemother; 2011 May; 55(5):2319-24. PubMed ID: 21321137
[TBL] [Abstract][Full Text] [Related]
9. Use of aminoglycoside 3' adenyltransferase as a selection marker for Chlamydia trachomatis intron-mutagenesis and in vivo intron stability.
Lowden NM; Yeruva L; Johnson CM; Bowlin AK; Fisher DJ
BMC Res Notes; 2015 Oct; 8():570. PubMed ID: 26471806
[TBL] [Abstract][Full Text] [Related]
10. Impact of Active Metabolism on Chlamydia trachomatis Elementary Body Transcript Profile and Infectivity.
Grieshaber S; Grieshaber N; Yang H; Baxter B; Hackstadt T; Omsland A
J Bacteriol; 2018 Jul; 200(14):. PubMed ID: 29735758
[TBL] [Abstract][Full Text] [Related]
11. Recombinant Human Peptidoglycan Recognition Proteins Reveal Antichlamydial Activity.
Bobrovsky P; Manuvera V; Polina N; Podgorny O; Prusakov K; Govorun V; Lazarev V
Infect Immun; 2016 Jul; 84(7):2124-2130. PubMed ID: 27160295
[TBL] [Abstract][Full Text] [Related]
12. A secondary structure motif predictive of protein localization to the chlamydial inclusion membrane.
Bannantine JP; Griffiths RS; Viratyosin W; Brown WJ; Rockey DD
Cell Microbiol; 2000 Feb; 2(1):35-47. PubMed ID: 11207561
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of
Mestrovic T; Ljubin-Sternak S
Front Biosci (Landmark Ed); 2018 Jan; 23(4):656-670. PubMed ID: 28930567
[No Abstract] [Full Text] [Related]
14. In vitro antichlamydial activity of garenoxacin against Chlamydia trachomatis.
Futakuchi N; Nakatani M; Takahata M; Mitsuyama J
J Infect Chemother; 2012 Aug; 18(4):428-35. PubMed ID: 22113367
[TBL] [Abstract][Full Text] [Related]
15. Affinities of beta-lactams for penicillin binding proteins of Chlamydia trachomatis and their antichlamydial activities.
Storey C; Chopra I
Antimicrob Agents Chemother; 2001 Jan; 45(1):303-5. PubMed ID: 11120983
[TBL] [Abstract][Full Text] [Related]
16. Transposon Mutagenesis in Chlamydia trachomatis Identifies CT339 as a ComEC Homolog Important for DNA Uptake and Lateral Gene Transfer.
LaBrie SD; Dimond ZE; Harrison KS; Baid S; Wickstrum J; Suchland RJ; Hefty PS
mBio; 2019 Aug; 10(4):. PubMed ID: 31387908
[TBL] [Abstract][Full Text] [Related]
17. Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron.
Slepenkin A; Enquist PA; Hägglund U; de la Maza LM; Elofsson M; Peterson EM
Infect Immun; 2007 Jul; 75(7):3478-89. PubMed ID: 17470544
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial Resistance Screening in Chlamydia trachomatis by Optimized McCoy Cell Culture System and Direct qPCR-Based Monitoring of Chlamydial Growth.
Meštrović T; Virok DP; Ljubin-Sternak S; Raffai T; Burián K; Vraneš J
Methods Mol Biol; 2019; 2042():33-43. PubMed ID: 31385269
[TBL] [Abstract][Full Text] [Related]
19. Identification of a strong and specific antichlamydial N-acylhydrazone.
Zhang H; Kunadia A; Lin Y; Fondell JD; Seidel D; Fan H
PLoS One; 2017; 12(10):e0185783. PubMed ID: 28973037
[TBL] [Abstract][Full Text] [Related]
20. Lack of mutation in macrolide resistance genes in Chlamydia trachomatis clinical isolates with decreased susceptibility to azithromycin.
Bhengraj AR; Srivastava P; Mittal A
Int J Antimicrob Agents; 2011 Aug; 38(2):178-9. PubMed ID: 21570258
[No Abstract] [Full Text] [Related]
[Next] [New Search]
